Q3 2022 Results
Company overview
Financial performance
Cardiovascular
Financial review
2022 priorities
Appendix
Innovation: Pipeline overview
Innovation: Clinical trials
Immunology
Neuroscience
Oncology
iscalimab - CD40 inhibitor
Indication
Phase
NCT03905525 TWINSS (CCFZ533B2201)
Sjögren's syndrome
Phase 2
Patients
260
Primary
Outcome
Measures
Change in EULAR Sjögren's syndrome Disease Activity Index (ESSDAI)
score and EULAR Sjögren's syndrome Patient Reported Index (ESSPRI)
score
Arms
Intervention
Target
Patients
Three dose arms of CFZ533
Placebo
Patients with Sjögren's syndrome
Read-out
Milestone(s)
2022
Publication
2023
References
Abbreviations
Other
55 Investor Relations | Q3 2022 Results
NOVARTIS | Reimagining MedicineView entire presentation